香港在2025年10月接待了18家新的全球公司,包括主要的药剂和技术公司,带动了7.7B的投资和22 000个工作岗位。 Hong Kong welcomed 18 new global firms in Oct 2025, including major pharma and tech companies, driving $7.7B in investment and 22,000 jobs.

香港吸引了100家全球战略企业,2025年10月有18家新公司加入,其中包括大型制药公司GlaxoSmithKline、Roche和Merck、中国的“小红树”和美国的“Vobile集团”公司。 Hong Kong has attracted 100 global strategic enterprises, with 18 new firms joining in October 2025, including major pharmaceutical companies GlaxoSmithKline, Roche, and Merck, China’s Xiaohongshu, and U.S. firm Vobile Group. 这些投资预计将带来600亿港元(77.1亿美元),并创造22 000个高质量就业机会。 The investments are projected to bring HK$60 billion ($7.71 billion) and create 22,000 high-quality jobs. 香港财政秘书陈保罗(Paul Chan)强调该市作为中国与全球市场之间桥梁的作用,其创新生态系统,以及海涛深圳-香港科技创新区和独立的药品审批制度等举措,以促进跨境合作和医疗创新。 Hong Kong’s Financial Secretary Paul Chan highlighted the city’s role as a bridge between China and global markets, its innovation ecosystem, and initiatives like the Hetao Shenzhen-Hong Kong Science and Technology Innovation Zone and an independent drug approval system to boost cross-border collaboration and medical innovation.